These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15048071)

  • 1. Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
    Scaramucci L; Niscola P; Buffolino S; Bongarzoni V; Cimino G; Montanaro M
    Hematol J; 2004; 5(2):186-7. PubMed ID: 15048071
    [No Abstract]   [Full Text] [Related]  

  • 2. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
    Tonino SH; van Gelder M; Eldering E; van Oers MH; Kater AP
    Leukemia; 2010 Mar; 24(3):652-4. PubMed ID: 19956201
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
    Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
    Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
    J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
    Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine in chronic lymphocytic leukaemia.
    Elter T; Hallek M; Engert A
    Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
    Liu Y; Zhu HL; Lu XC; Li SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):989-92. PubMed ID: 17956676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
    Tempescul A; Feuerbach J; Ianotto JC; Dalbies F; Marion V; Le Bris MJ; De Braekeleer M; Berthou C
    Ann Hematol; 2009 Jan; 88(1):85-8. PubMed ID: 18654781
    [No Abstract]   [Full Text] [Related]  

  • 17. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
    Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
    Krejci M; Doubek M; Brychtova Y; Stehlikova O; Chovancova J; Tichy B; Francova HS; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Jan; 92(2):249-54. PubMed ID: 23014659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing the way we think about chronic lymphocytic leukemia.
    Lin TS; Grever MR; Byrd JC
    J Clin Oncol; 2005 Jun; 23(18):4009-12. PubMed ID: 15767640
    [No Abstract]   [Full Text] [Related]  

  • 20. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
    Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.